AzTrials
AzTrials

Postoperative DeliriumNCT07369466

Association of Preoperative Hippocampal Glucose Metabolism With Postoperative Delirium in Older Diabetic Patients

An observational study of Postoperative Delirium and Type 2 Diabetes, run by Chinese PLA General Hospital.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

Objective: To investigate the association between preoperative hippocampal glucose metabolism levels and the risk of postoperative delirium (POD) in elderly patients with type 2 diabetes (T2DM), and to provide a prospective neuroimaging biomarker for identifying high-risk populations. Read more about this study

Who is it for?
Ages 65 years and older
Conditions the study is for
Postoperative Delirium, Type 2 Diabetes
How many people
154 participants
Where
No sites listed yet
Study dates
1 Feb 2026to 1 Jun 2028
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 65 years and older
  • All sexes
  • No healthy volunteers
  • Older adult

Study population: This prospective cohort study will enroll elderly patients (age ≥ 65 years) diagnosed with type 2 diabetes mellitus (T2DM) who are scheduled for elective liver tumor resection surgery with an expected duration of >2 hours at the First Medical Center of Chinese PLA General Hospital. All participants will undergo preoperative ¹⁸F-FDG PET/CT scanning and cognitive assessment, and will be prospectively followed for the occurrence of postoperative delirium.

Who may be able to join

  • Diagnosed with type 2 diabetes mellitus (T2DM).
  • Age ≥ 65 years.
  • Scheduled for elective liver tumor resection surgery with an expected operative duration > 2 hours.
  • Underwent whole-body ¹⁸F-FDG PET/CT scan within 1 month prior to surgery.

Who cannot join

  • Patient declines to participate.
  • Inability to cooperate with cognitive assessments or a preoperative Mini-Mental State Examination (MMSE) score < 23.
  • American Society of Anesthesiologists (ASA) physical status classification ≥ IV.
  • History of organic brain disorders, including stroke, traumatic brain injury, or intracranial tumors.
  • History of psychiatric disorders or current use of antipsychotic medications.

Trial locations and contacts

No sites are listed yet. Contact the study team or a site near you to ask about taking part.

Weidong Mi, Professor contact

86+13381082966

wwdd1962@163.com

Danyang Geng, Master contact

86+17367522284

sphm123@126.com

About this study

Official title: Preoperative Hippocampal Glucose Metabolism Levels and the Risk of Postoperative Delirium in Older Patients With Type 2 Diabetes: A Prospective Cohort Study

Objective: To investigate the association between preoperative hippocampal glucose metabolism levels and the risk of postoperative delirium (POD) in elderly patients with type 2 diabetes (T2DM), and to provide a prospective neuroimaging biomarker for identifying high-risk populations.

Methods: This prospective cohort study plans to enroll 154 elderly T2DM patients scheduled for liver tumor resection at the First Medical Center of Chinese PLA General Hospital. Baseline cognitive function will be assessed using the Mini-Mental State Examination (MMSE) one day before surgery. Hippocampal glucose metabolism will be quantitatively evaluated by measuring the mean standardized uptake value (SUVmean) of bilateral hippocampi using ¹⁸F-FDG PET/CT. POD will be assessed twice daily from postoperative days 1 to 7 using the 3-Minute Diagnostic Interview for CAM (3D-CAM). The correlation between preoperative hippocampal SUVmean and POD incidence will be analyzed using univariate and multivariate logistic regression models. The predictive performance will be evaluated by constructing receiver operating characteristic (ROC) curves. Furthermore, the relationship between a peripheral insulin resistance marker (the triglyceride-glucose index, TyG index) and hippocampal metabolism levels will be analyzed.

Significance: This study aims to determine whether impaired preoperative hippocampal metabolism serves as an independent risk factor for POD. The findings are expected to provide a prospective functional neuroimaging biomarker for the early warning of POD and offer a theoretical basis for developing precise prevention strategies targeting cerebral metabolic abnormalities. This will facilitate the application of neuroimaging techniques in the field of perioperative brain dysfunction monitoring.

Keywords
Postoperative delirium, Type 2 Diabetes Mellitus, Positron-Emission Tomography, Hippocampus, Glucose metabolism
Medical subject headings
Emergence Delirium, Diabetes Mellitus, Type 2

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT07369466
Study groupRoleWhat they receive
Older T2DM Hepatectomy CohortNot described

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Incidence of Postoperative Delirium (POD)

    Assessed by the 3-Minute Diagnostic Interview for CAM (3D-CAM), administered twice daily.

    Measured: From surgery completion to postoperative day 7

Secondary outcomes (1)
  1. Triglyceride-glucose (TyG) index

    Calculated as Ln [fasting triglycerides (mg/dL) × fasting glucose (mg/dL) / 2].

    Measured: Within 7 days before surgery (preoperative baseline)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted27 Jan 2026
  2. Study start1 Feb 2026 (estimated)
  3. Primary completion1 Feb 2028 (estimated)
  4. Study completion1 Jun 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
154 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07369466
Sponsor's protocol ID
PLAGH-PET-01
Status last verified
Jan 2026
First submitted
10 Jan 2026
Last updated
27 Jan 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided: A data sharing plan has not been fully formulated yet and will be finalized prior to the completion of the study.

Questions about this trial

What is this clinical trial studying?

An observational study of Postoperative Delirium and Type 2 Diabetes, run by Chinese PLA General Hospital.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 27 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Weidong Mi, Professor (86+13381082966, wwdd1962@163.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Incidence of Postoperative Delirium (POD) (time frame: From surgery completion to postoperative day 7). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Jan 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in